BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25201135)

  • 1. Mid-regional pro-adrenomedullin: an indicator of the failing Fontan circuit in patients with univentricular hearts?
    Kaiser R; Abdul-Khaliq H; Wilkens H; Herrmann E; Raedle-Hurst TM
    Eur J Heart Fail; 2014 Oct; 16(10):1082-8. PubMed ID: 25201135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
    Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
    Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
    Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
    Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction.
    Elmas E; Lang S; Dempfle CE; Kälsch T; Papassotiriou J; Morgenthaler NG; Borggrefe M; Brueckmann M
    Int J Cardiol; 2008 Aug; 128(1):107-11. PubMed ID: 17698224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
    Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
    Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
    Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
    Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
    Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
    Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
    Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
    J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
    Hauser JA; Demyanets S; Rusai K; Goritschan C; Weber M; Panesar D; Rindler L; Taylor AM; Marculescu R; Burch M; Wojta J; Michel-Behnke I
    Heart; 2016 Oct; 102(20):1633-9. PubMed ID: 27220692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
    Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
    Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
    Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
    Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome.
    Zhang F; Li X; Ochs T; Chen L; Liao Y; Tang C; Jin H; Du J
    J Am Coll Cardiol; 2012 Jul; 60(4):315-20. PubMed ID: 22813609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
    Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
    Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.